What criteria do patients use when judging the effectiveness of psoriasis management?

Journal of Evaluation in Clinical Practice

Volumn 8, Issue 4, 2002, Pages 367-376

  Ersser, Steven J ^a   Surridge, Heidi ^a   Wiles, Anne ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b OXFORD BROOKES UNIVERSITY   (United Kingdom)

Author keywords

Clinical effectiveness; Ethnography; Outcome measurement; Patient evaluation; Psoriasis therapy; Qualitative research

Indexed keywords

ADULT; ARTICLE; HUMAN; PRIORITY JOURNAL; PRURITUS; PSORIASIS; SCALP; SELF CARE; TREATMENT OUTCOME; CULTURAL ANTHROPOLOGY; DERMATOLOGY; FEMALE; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITATIVE RESEARCH; REVIEW;

ADULT; ANTHROPOLOGY, CULTURAL; DERMATOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUALITATIVE RESEARCH; TREATMENT OUTCOME;

EID: 0036859019     PISSN: 13561294     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2753.2002.00372.x     Document Type: Article

References (71)

1. Assal J.R (1998) Revisiting the approach to treatment of long-term illness: From the acute to the chronic state: A need for educational and managerial skills for long term follow-up. Patient Education and Counselling 37, 99-111.
2. Belsito D.V. & Kechijian P. (1982) The role of tar in Goeckerman therapy. Archives of Dermatology 118 (5), 319-321.
3. Berth-Jones J. & Hutchinson P.E. (1992) Progress in self treatment for psoriasis vulgaris. Journal of Clinical Pharmacological Therapy 17 (4), 217-222.
4. Bittiner S.B., Tucker W.F., Cartwright I. & Bleehen S.S. (1988) A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet 1 (8582), 378-380.
5. Blaxter M. (1995) Consumers and Research in the NHS. Department of Health, Leeds.
6. Bonifati C., Carducci M., Mussi A. & D'Auria L. (1998) Recognition and treatment of psoriasis. Special considerations in elderly patients. Drugs and Aging 12 (3), 177-190.
7. Britten N. (1995) Qualitative interviews in medical research. British Medical Journal 311, 251-253.
8. Burrall B.A., Dijkstra J.W.E., Lowe N.J. & Maibach H.I. (1995) Psoriasis therapies: Old, new, and borrowed. Patient Care 30, 38-66.
9. Clark A.R. (1996) Simplified treatment of psoriasis for the adult patient. Journal of the American Academy of Physician Assistants April, 63-74.
10. Cowen P. (1996) New horizons in the treatment of psoriasis and cutaneous fungal infections. Australian Family Physician 25, 317-322.
11. Cram D.L. (1976) Psoriasis: Treatment with tar gel. Cutis 17, 1197-1198.
12. Cullen S.I. (1996) Long-term effectiveness and safety of topical calcipotriene for psoriasis. South Medical Journal 89, 1053-1056.
13. Department of Health (1995) Consumers and Research in the NHS: An R and D Contribution to Consumer Involvement in the NHS. Department of Health, Leeds.
14. Department of Health (1998) A First Class Service. HMSO, London. Department of Health (2000) The NHS Plan: A Plan for Investment: A Plan for Reform, Command Paper: Cm4818-Stationers Office, London.
15. Dodd W.A. (1993) TARS. Their role in the treatment of psoriasis. Dermatology Clinics 11 (1), 131-135.
16. Ersser S.J. (1997) Nursing as a Therapeutic Activity: An Ethnography. Avebury, Aldershot.
17. Farber E.M., Abel E.A. & Charuworn A. (1983) Recent advances in the treatment of psoriasis. Journal of the American Academy of Dermatology 8 (3), 311-321.
18. Feldman S.R., Fleischer A.B., Reboussion D.M et al. (1996) The Self-Administered Psoriasis Area and Severity Index is valid and reliable. Journal of Investigative Dermatology 106 (1), 183-186.
19. Finlay A.Y. (1997) Quality of life measurement in dermatology: A practical guide. British Journal of Dermatology 136, 305-314.
20. Finlay A.Y. & Khan G.K. (1994) Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical Experimental Dermatology 19, 210-216.
21. Fitzpatrick R. & Hopkins A. (1983) Problems in the conceptual framework of patient satisfaction research: An empirical exploration. Sociology of Health and Illness 5 (3), 297-311.
22. Fleischer A.B., Feldman S.R. & Dekle C.L. (1999) The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. Journal of Dermatology 26 (4), 210-215.
23. Fleischer A.B., Feldman S.R., Rapp S.R et al. (1996) Disease severity measures in a population of psoriasis patients: The symptoms of psoriasis correlate with Self-Administered Psoriasis Area Severity Index scores. Journal of Investigative Dermatology 107 (1), 26-29.
24. Foged E.K. & Schmidt H. (1984) Treatment modalities of psoriatics over a 6-year period (1975-81). Dermatologica 168 (2), 90-93.
25. Fortune D.G., Richards H.L., Main C.J. & Griffiths C.E.M. (1998) What patients with psoriasis believe about their condition. Journal of the American Academy of Dermatology 39 (2), 283-284.
26. Fredricksson T. & Petterson U. (1978) Severe psoriasis: Oral therapy with a new retinoid. Dermatologica 157, 238-244.
27. Fredriksson T. (1983) A comparative study of dithranol cream, 0.25% and 0.1%, and dithranol ointment 0.25% in the treatment of psoriasis. Pharmatherapeutica 3 (7), 496-498.
28. Fried R.G., Friedman S., Paradis C et al. (1995) Trivial or terrible? The psychosocial impact of psoriasis. International Journal of Dermatology 33, 101-105.
29. Fry L. (1988) Psoriasis. British Journal of Dermatology 119, 445-461.
30. Ginsberg I.H. (1995) Psychological and psychophysiological aspects of psoriasis. Dermatology Clinics 13, 793-804.
31. Glaser B.G. (1978) Theoretical Sensitivity. The Sociology Press, San Francisco, CA.
32. Gollick H.P. (1996) Oral retinoids - Efficacy and toxicity in psoriasis. British Journal of Dermatology 135 (Suppl. 49), 6-17.
33. Gonzalez E. (1995) PUVA for psoriasis. Dermatology Clinics 13 (4), 851-866.
34. Greenhalgh T. & Hurwitz B. (1998) Narrative Based Medicine. Dialogue and Discourse in Clinical Practice. BMJ Publishing Group, London.
35. Griffiths C.E.M., Clark C.M., Chalmers R.J.G et al. (2000) A systematic review of treatments for severe psoriasis. Health Technology Assessment 4 (40) [entire issue].
36. Haynes R., Taylor D. & Sackett P. (1979) Compliance in Health Care John Hopkins University Press, Baltimore.
37. Jegasothy B.V., Ackerman C.D., Todo S et al. (1992) Tacrolimus (FK 506) - a new therapeutic agent for severe recalcitrant psoriasis. Archives of Dermatology 128, 781-784.
38. Jobling R. (1976) Psoriasis: A preliminary questionnaire study of sufferer's subjective experience. Clinical and Experimental Dermatology 1, 233-236.
39. Jobling R. (1977) Learning to live with it: An account of a career of chronic dermatological illness and patienthood. In Medical Encounters: The Experience of Illness and Treatment (eds A. Davis & G. Horobin), pp. 72-86. Croom-Helm, London.
40. Jobling R. (1988) The experience of psoriasis under treatment. In Living with Chronic Illness (eds R. Anderson & M. Bury), pp. 225-244. Hyman Unwin, London.
41. Jobling R. (1992) Psoriasis and its treatment in psychosocial perspective. Reviews in Contemporary Pharmacotherapy 3, 339-345.
42. Jowett S. & Ryan T. (1985) Skin disease and handicap: An analysis of the impact of skin conditions. Social Science and Medicine 20 (4), 425-429.
43. Kabat-Zinn J., Wheeler E., Light T et al. (1998) Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosomatic Medicine 60, 625-632.
44. Kanzler M.H. & Gorsulowsky D.C. (1993) Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. British Journal of Dermatology 129,310-314.
45. Kar P.K., Jha P.K. & Snehi P.S. (1994) Evaluation of Psoralen with solar ultraviolet (Puvasol) and adjunctive topical tar therapy in psoriasis. Journal of the Indian Medical Association 9, 120-121.
46. Kragballe K. (1995) Calcipotriol: A new drug for topical psoriasis treatment. Pharmacological Toxicology 77, 241-246.
47. Larko O. (1982) Phototherapy of psoriasis - Clinical aspects and risk evaluation. Acta Dermatologica 103 (Suppl.), 13-42.
48. Layton A.M., Sheehan-Dare R.A., Goodfield M.J. & Cotterill J.A. (1989) Hydroxyurea in the management of therapy resistant psoriasis. British Journal of Dermatology 121 (5), 647-653.
49. Liem W.H., McCullough J.L. & Weinstein G.D. (1995) Effectiveness of topical therapy for psoriasis: Results of a national survey. Cutis 55, 306-310.
50. Long A.F. & Dixon P. (1996) Monitoring outcomes in routine practice: Defining appropriate measurement criteria. Journal of Evaluation in Clinical Practice 2 (1), 71-78.
51. McKenna K.E. & Stern R.S. (1996) The outcomes movement and new measures of the severity of psoriasis. Comment. Journal of the American Academy of Dermatology 36 (3), 502-503.
52. Mitchell C. (1983) Case and situation analysis. Sociological Review 31 (2), 187-211.
53. Nevitt G.J. & Hutchinson P.E. (1996) Psoriasis in the community: Prevalence, severity and patients beliefs and attitudes towards the disease. British Journal of Dermatology 135, 533-537.
54. O'Neill P. & Kelly P. (1996) Postal questionnaire study of disability in the community associated with psoriasis. British Medical Journal 313 (7062), 919-921.
55. Oliver S. (1997) Exploring lay perspectives on questions of effectiveness. In Non-Random Reflections on Health Services Research (eds A. Maynard & I. Chalmers), pp. 272-291. BMJ Publishing Group, London.
56. Park B.S. & Youn J.I. (1998) Factors influencing psoriasis: An analysis based upon the extent of involvement and clinical type. Journal of Dermatology 25 (2), 97-102.
57. Pendleton D., Schofield T., Tate P. & Havelock P. (1984) The Consultation: An Approach to Learning and Teaching. Oxford University Press, Oxford.
58. Petrozzi J.W., Barton J.O., Kligman A. & de los Reyes O. (1979) Topical methoxsalen administration and sunlamp fluorescent irradiation in psoriasis. Archives of Dermatology 115 (4), 436-439.
59. Portnoy B. & Beck M.H. (1981) The treatment of active chronic psoriasis: A comparison of the effectiveness of a preparation containing 0.1% dithranologica and 17% urea in a cream base and 0.1% dithranologica in Lassar'a past B.P.C. Acta Dermato-Venereologica (Stockholm) 61 (5, Suppl.), 459-461.
60. Root S., Kent G. & Al-Abadie M.S.K. (1994) The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology 189, 234-237.
61. Sackett D.L., Richardson W.S., Rosenberg W. & Haynes R.S. (1997) Evidence Based Medicine: How to Teach and Practice EBM. Churchill Livingstone, New York.
62. Spradley J.P. (1979) The Ethnographic Interview. Holt, Rinehart and Winston, New York.
63. Spuls P.I., Witkamp L., Bossuyt P.M. & Bos J.D. (1997) A systematic review of five systemic treatments for severe psoriasis. British Journal of Dermatology 137 (6), 943-949.
64. Stern R.S. (1988) The benefits, costs and risks of topical tar preparations in the treatment of psoriasis: Considerations of cost effectiveness. Annals of the Academy of Medicine of Singapore 17, 473-476.
65. Tuckett D., Boulton M., Olson C. & Williams A. (1985) Meetings Between Experts: An Approach to Sharing Medical Ideas in Medical Consultations. Tavistock, London.
66. Veien N.K., Bjerke J.R., Rossmann-Ringdahl I. & Jakobsen H.B. (1997) Once daily treatment of psoriasis with calcipotriol compared with twice daily treatment with calcipotriol. A double-blind trial. Dermatology Clinics 137 (4), 581-586.
67. Weinstein G.D. & White G.M. (1993) An approach to the treatment of moderate to severe psoriasis with rotational therapy. Journal of the American Academy of Dermatology 28 (3), 454-459.
68. Williams R. (1985) PUVA therapy vs. Goeckerman therapy in the treatment of psoriasis: A pilot study. Physiotherapy Canada 37 (6), 361-366.
69. Williams H. (1997) Dermatology Health Care. Needs Assessment. Radcliffe Medical Press, Oxford.
70. Young E. (1986) Treatment of psoriasis with dithranol cream compared with dithranol paste. Dermatologica 173 (6), 285-287.
71. Ziboh V.A., Cohen K.A., Ellis C.N et al. (1986) Effects of dietary supplementation of fish oil on neutrophil and epidermal fatty acids. Modulation of clinical course of psoriatic subjects. Archives of Dermatology 122 (11), 1277-1282.